[HPV-associated pathology of the oral mucosa and anogenital area. (Rationale for combined therapy)]. / VPCh-assotsiirovannaya patologiya slizistoi obolochki rta i anogenital'noi oblasti. (Opyt primeneniya kombinirovannoi terapii).

THE AIM OF THE STUDY: Was to evaluate the effectiveness and duration without a relapse period in patients with HPV-associated pathology of the oral mucosa and in combination with lesions of the anogenital region during combined therapy, including destruction and Panavir. MATERIALS AND METHODS: The study included 60 women diagnosed with «Viral warts. Genital condyloma of the oral cavity. 15 patients were also diagnosed with «Anogenital warts¼. The patients were divided into three groups of 20 women (15 with HPV-associated pathology of the oral cavity; 5 with combined HPV-associated pathology of the oral cavity and anogenital area). In the first group, the drug Panavir was administered intravenously. Between the third and fourth injections radiosurgical destruction of condylomas was carried out followed by Panavir gel applications until complete epithelialization of the destruction zone and further use of Panavir-inlight spray in the oral cavity and Panavir-intim spray in the anogenital area for 4 weeks. In the second group, the destruction of genital warts was carried out only with local treatment identical to that in the first group. In the third group after destruction applications of an oil solution of vitamin A were added to the oral mucosa 3-4 times a day until complete epithelization of the lesion, an alcohol solution of fucorcin and panthenol cream were applied externally in the anogenital area. RESULTS: According to clinical and laboratory monitoring after 3, 6 and 12 months, HPV elimination in the first group was achieved in 70, 85 and 90% of cases; in the second group in 50, 75 and 80%; in the third group in 30, 40 and 40%, respectively; within 12 months, relapses in the first group were registered in 10% of cases; in the second and third groups in 20% and 45% of cases, respectively. CONCLUSION: Combined therapy including destruction and complex use of different dosage forms of the drug Panavir showed higher clinical efficacy and allowed to achieve a reduction in the rate of condyloma relapses.

[Herpes simplex as a complex interdisciplinary problem. Clinical case]. / Prostoi gerpes ­ «neprostaya¼ mezhdistsiplinarnaya problema. Klinicheskii sluchai.

THE PURPOSE OF THE STUDY: To show the effectiveness of the use of the drug Panavir in patients with a combined clinical manifestation of viral herpetic lesions of the oral mucosa and genital area. MATERIAL AND METHODS: Patient S., 42 years old, complained of discomfort, pain and rashes in the mouth and on the genitals. To assess the patient's condition, clinical (dental examination using luminescent stomatoscopy and dermatovenerological examination) and laboratory methods were used: clinical blood and urine tests, microscopy of smears from the urethra, cervical canal, vagina, rectum and PCR-examination of the discharge from the elements of the lesion of the oral mucosa, urethra, cervical canal and the contents of vesicular rashes on the skin of the perianal area. RESULTS: The prescribed antiviral treatment with the inclusion of 0.004% Panavir scheme in the form of injections and drugs for topical use on the oral mucosa, genitals and on the skin, made it possible to quickly achieve a resolution of the inflammatory infectious process. On the third day after the start of therapy, the patient noted a decrease in the area of inflammation. Subjective sensations in the form of discomfort during urination, burning and soreness in the foci were leveled. After 7 days, the foci in the mouth and on the skin of the perianal area completely regressed. CONCLUSION: The use of Panavir in the complex treatment of severe forms of recurrent herpes virus lesions of the oral mucosa and genital area has shown its high efficiency, good tolerability, no side effects and an increase in the remission period.